Status:
COMPLETED
A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers
Lead Sponsor:
Arena Pharmaceuticals
Conditions:
Healthy
Eligibility:
All Genders
19-45 years
Phase:
PHASE1
Brief Summary
The APD791-002 study is designed primarily to evaluate the safety, tolerability, and pharmacokinetics of APD791 when administered for 7 days to healthy adult subjects.
Eligibility Criteria
Inclusion
- Healthy adult men and women, ages 19-45
- Non smokers
Exclusion
- History of a bleeding disorder
- Use of any drug known to have an effect on coagulation or clotting or any anti-platelet therapy within 2 weeks of the screening
- Recently donated blood or had significant blood loss
- Current use of a prescription medication
- Pregnant females
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00619931
Start Date
January 1 2008
End Date
June 1 2008
Last Update
July 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MDS Pharma Services
Lincoln, Nebraska, United States, 68502